参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Dermatofibrosarcoma Protuberans Version 1.2019 — August 31,2018.
2.Uysal B,Sager O,Gamsiz H,et al.Evaluation of the role of radiotherapy in the management of dermatofibrosarcoma protuberans.J BUON 2013, 18:268-273.
3.Mentzel T,Pedeutour F,Lazar A,et al.Dermatofibrosarcoma Protuberans in WHO Classification of Tumors of Soft Tissue and Bone.In:Fletcher CD,Bridge JA,Hogendoorn PCW,Mertens F,eds (ed 4):IARC Press; 2013.
4.Yan X,Takahara M,Xie L,et al.Cathepsin K expression:a useful marker for the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.Histopathology 2010, 57:486-488.
5.Criscione VD,Weinstock MA.Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States,1973 to 2002.J Am Acad Dermatol 2007, 56:968-973.
6.Hamid R,Hafeez A,Darzi MA,et al.Outcome of wide local excision in dermatofibrosarcoma protuberans and use of radiotherapy for margin-positive disease.Indian Dermatol Online J 2013, 4:93-96.
7.Farma JM,Ammori JB,Zager JS,et al.Dermatofibrosarcoma protuberans:how wide should we resect? Ann Surg Oncol 2010, 17:2112-2118.
8.Kimmel Z,Ratner D,Kim JY,et al.Peripheral excision margins for dermatofibrosarcoma protuberans:a metaanalysis of spatial data.Ann Surg Oncol 2007, 14:2113-2120.
9.Castle KO,Guadagnolo BA,Tsai CJ,etal.Dermatofibrosarcoma protuberans:long-term outcomes of 53 patients treated with conservative surgery and radiation therapy.Int J Radiat Oncol Biol Phys 2013, 86:585-590.
10.Rutkowski P,Van Glabbeke M,Rankin CJ,et al.Imatinib mesylate in advanced dermatofibrosarcoma protuberans:pooled analysis of two phase II clinical trials.J Clin Oncol 2010, 28:1772-1779.
11.McArthur GA.Molecular targeting of dermatofibrosarcoma protuberans:a new approach to a surgical disease.J Natl Compr Canc Netw 2007, 5:557-562.
12.Williams N,Morris CG,Kirwan JM,et al.Radiotherapy for Dermatofibrosarcoma Protuberans.Am J Clin Oncol 2013.(https://www.daowen.com)
13.Sellheyer K,Nelson P,Krahl D.Dermatofibrosarcoma protuberans:a tumour of nestin-positive cutaneous mesenchymal stem cells? Br J Dermatol 2009, 161:1317-1322.
14.Ugurel S,Utikal J,Mohr P,et al.Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP):A phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) ［abstract］.J Clin Oncol 2006, 24(Suppl 18):Abstract 9561.
15.Connective Tissue Tumors.In:Calonje E,Brenn T,Lazar A,McKee PH,eds.McKee’s Pathology of the Skin with Clinical Correlations (ed 4):Elsevier Saunders, 2012:1630-1635.
16.Meguerditchian AN,Wang J,Lema B,et al.Wide Excision or Mohs Micrographic Surgery for the Treatment of Primary Dermatofibrosarcoma Protuberans.Am J Clin Oncol 2009.
17.Pennington BE,Leffell DJ.Mohs micrographic surgery:established uses and emerging trends.Oncology (Williston Park) 2005, 19:1165-1171; discussion 1171-1162,1175.
18.Buck DW, Kim JY,Alam M,et al.Multidisciplinary approach to the management of dermatofibrosarcoma protuberans.J Am Acad Dermatol 2012, 67:861-866.
19.Rouhani P,Fletcher CD,Devesa SS, et al.Cutaneous soft tissue sarcoma incidence patterns in the U.S.:an analysis of 12,114 cases.Cancer 2008, 113:616-627.
20.Labropoulos SV,Fletcher JA,Oliveira AM,et al.Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.Anticancer Drugs 2005, 16:461-466.
21.Bogucki B,Neuhaus I,Hurst EA.Dermatofibrosarcoma Protuberans:A Review of the Literature.Dermatol Surg 2012.
22.Lisovsky M,Hoang MP,Dresser KA,et al.Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms:a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.Mod Pathol 2008, 21:31-38.
23.Foroozan M,Sei JF,Amini M,et al.Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans:systematic review.Arch Dermatol 2012, 148:1055-1063.